Disease Info Card

Conjugated Hyperbilirubinemia

Information about Conjugated Hyperbilirubinemia: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Conjugated Hyperbilirubinemia

Most recent studies have shown that Conjugated Hyperbilirubinemia shares some biological mechanisms with anemia, atresia, biliary-atresia, biliary-tract-diseases, cholestasis, hemolysis-(disorder), hepatitis, hyperbilirubinemia, hyperbilirubinemia-hereditary, icterus, intrahepatic-cholestasis, jaundice-chronic-idiopathic, jaundice-obstructive, liver-cirrhosis, liver-damage, liver-diseases, neonatal-hepatitis, neonatal-jaundice, systemic-infection, unconjugated-hyperbilirubinemia.

Among the many pathways, these few ones have gauged particular interests from scientists studying Conjugated Hyperbilirubinemia, and have been seen in publications frequently: Anion Transport, Bilirubin Transport, Cell Migration, Coagulation, Conjugation, Excretion, Flocculation, Gallstone Formation, Immune Response, Intestinal Absorption, Liver Regeneration, Localization, Mating, Organic Anion Transport, Pathogenesis, Pigment Accumulation, Pigmentation, Protein Maturation, Secretion, Transport

Quite a number of genes have been found to play important roles in Conjugated Hyperbilirubinemia, such as ABCC1, ABCC2, ABCC3, ABCC6, ALB, CD55, F2, GGT1, GGT2, KLHL1, MARCKSL1, POMC, RANGAP1, RDX, SERPINA1, SLC17A5, SLC25A13, WLS. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.